Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 3
2013 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.
Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA). Simner PJ, et al. Among authors: tailor f. Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-34. doi: 10.1016/j.diagmicrobio.2010.10.029. Diagn Microbiol Infect Dis. 2011. PMID: 21353961
Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.
Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. Lagacé-Wiens PR, et al. Among authors: tailor f. Antimicrob Agents Chemother. 2011 May;55(5):2434-7. doi: 10.1128/AAC.01722-10. Epub 2011 Feb 28. Antimicrob Agents Chemother. 2011. PMID: 21357295 Free PMC article.
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).
Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J; Canadian Antimicrobial Resistance Alliance; Hoban DJ. Zhanel GG, et al. Among authors: tailor f. Antimicrob Agents Chemother. 2010 Nov;54(11):4684-93. doi: 10.1128/AAC.00469-10. Epub 2010 Aug 30. Antimicrob Agents Chemother. 2010. PMID: 20805395 Free PMC article.
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J; Canadian Antimicrobial Resistance Alliance (CARA); Hoban DJ. Zhanel GG, et al. Among authors: tailor f. Antimicrob Agents Chemother. 2008 Apr;52(4):1430-7. doi: 10.1128/AAC.01538-07. Epub 2008 Feb 19. Antimicrob Agents Chemother. 2008. PMID: 18285482 Free PMC article.
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance. Denisuik AJ, et al. Among authors: tailor f. J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027. J Antimicrob Chemother. 2013. PMID: 23587779
Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.
Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). Lagacé-Wiens PR, et al. Among authors: tailor f. Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-9. doi: 10.1016/j.diagmicrobio.2010.10.027. Diagn Microbiol Infect Dis. 2011. PMID: 21353959
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA. Zhanel GG, et al. Among authors: tailor f. J Antimicrob Chemother. 2009 Oct;64(4):824-8. doi: 10.1093/jac/dkp254. Epub 2009 Jul 29. J Antimicrob Chemother. 2009. PMID: 19643776